Isocitrate dehydrogenase/IDH1 Mouse monoclonal Antibody IgG1
Fig1: Western blot analysis of IDH1 on different cell lysates using anti-IDH1 antibody at 1/1000 dilution.
Lane 1: Hela
Lane 2: HepG2
Lane 3: A431
Lane 4: MCF-7
Lane 5: A549
Lane 6: Jurkat
Lane 7: Human kidney
Lane 8: Human brain
Lane 9: Human liver
Fig2: Immunohistochemical analysis of paraffin-embedded human colon carcinoma tissue using anti-IDH1 antibody. Counter stained with hematoxylin.
Fig3: Immunohistochemical analysis of paraffin-embedded human breast tissue using anti-IDH1 antibody. Counter stained with hematoxylin.
Host Species; Species ReactivityMouse; Human, Zebrafish
Application SummaryWB, IHC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesIsocitRate dehydrogenase [NADP] cytoplasmic,Cytosolic NADP-isocitRate dehydrogenase,IDP,NADP(+)-specific ICDH,Oxalosuccinate decarboxylase
BackgroundIsocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as the mitochondrion and peroxisome. Mutations in IDH1 are also implicated in cancer. Originally mutations in IDH1 were detected in an integrated genomic analysis of human glioblastoma multiforme. In addition to being mutated in diffuse gliomas, IDH1 has also been shown to harbor mutations in human acute myeloid leukemia (AML).(EM40705)